

Manuel Comabella

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3532069/manuel-comabella-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

227
papers

11,643
citations

49
h-index

103
g-index

248
ext. papers

14,165
ext. citations

6.8
avg, IF

5.73
L-index

#	Paper	IF	Citations
227	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.. <i>Journal of Neurology</i> , 2022 , 269, 1764	5.5	0
226	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	3
225	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221089540	5	1
224	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage.. <i>Clinical and Translational Medicine</i> , 2022 , 12, e837	5.7	0
223	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the - Gene Region in Immature Dendritic Cells.. <i>Frontiers in Immunology</i> , 2021 , 12, 816930	8.4	0
222	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. <i>Neurology</i> , 2021 , 96, e482-e490	6.5	6
221	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211053001	5	0
220	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. <i>Frontiers in Immunology</i> , 2021 , 12, 760546	8.4	0
219	Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1455-1457	5	0
218	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
217	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211010082	5	2
216	Angiogenin in the Neurogenic Subventricular Zone After Stroke. <i>Frontiers in Neurology</i> , 2021 , 12, 662235	4.1	2
215	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 685139	8.4	3
214	Targeting Inflammasomes to Treat Neurological Diseases. <i>Annals of Neurology</i> , 2021 , 90, 177-188	9.4	7
213	Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
212	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021 , 28, 3384-3395	6	60
211	CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5

210	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 913-921	5	7
209	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
208	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021 , 97, e1641-e1652	6.5	6
207	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
206	Immunomodulatory Effects Associated with Cladribine Treatment.. <i>Cells</i> , 2021 , 10,	7.9	1
205	Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. <i>Epigenomics</i> , 2020 , 12, 2065-2076	4.4	4
204	A Polymorphism Within the Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020 , 11, 771	8.4	2
203	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. <i>Human Mutation</i> , 2020 , 41, 1308-1320	4.7	0
202	Chitinase 3-like 1 is neurotoxic in primary cultured neurons. <i>Scientific Reports</i> , 2020 , 10, 7118	4.9	7
201	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348	11.6	13
200	Modelling multiple sclerosis using induced pluripotent stem cells. <i>Journal of Neuroimmunology</i> , 2020 , 349, 577425	3.5	3
199	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020 , 11, 579438	4.1	5
198	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020 , 95, 436-444	6.5	44
197	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 912-923	5	26
196	A pharmacogenetic study implicates in the response to Interferon- β in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1074-1082	5	1
195	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1658-1669	5	18
194	The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1329-1339	5	7
193	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. <i>Brain</i> , 2020 , 143, 1414-1430	11.2	41

192	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019 , 365,	33.3	309
191	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019 , 92, e1507-e1516	6.5	31
190	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1535-1538	5	3
189	Simultaneous CMV and infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019 , 92, 296-298	6.5	13
188	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27	3.5	9
187	Biomarkers in Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	34
186	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018 , 141, 1075-1084	11.2	64
185	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018 , 141, 1085-1093	11.2	72
184	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
183	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 301-312	5	55
182	Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 322-330	5	45
181	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1507-1510	5	5
180	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1362-1371	5.3	8
179	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2018 , 15, 296	10.1	5
178	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018 , 175, 1679-1687	16.7	72
177	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018 , 15, 265	10.1	14
176	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018 , 14, 577-589	15	627
175	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. <i>European Journal of Neurology</i> , 2018 , 25, 1189-1191	6.1	35

174	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017 , 17, 312-318	3.5	19
173	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017 , 303, 62-65	3.5	8
172	Metabolomic signatures associated with disease severity in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e321	9.1	57
171	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128
170	Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. <i>Scientific Reports</i> , 2017 , 7, 13544	4.9	9
169	Reply. <i>Annals of Neurology</i> , 2017 , 82, 647-648	9.4	
168	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017 , 82, 186-195	9.4	13
167	Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. <i>Stem Cell Research</i> , 2017 , 24, 155-159	1.6	7
166	Lesion topographies in multiple sclerosis diagnosis: A reappraisal. <i>Neurology</i> , 2017 , 89, 2351-2356	6.5	19
165	Decreased soluble IFN- β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 937-945	5	7
164	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017 , 12, e0170395	3.7	27
163	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017 , 146, 67-84	3	18
162	Are Leber's mitochondrial DNA mutations associated with aquaporin-4 autoimmunity?. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 393-4	5	5
161	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016 , 87, 1368-74	6.5	37
160	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016 , 87, 2491-2494	6.5	17
159	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016 , 92, 333-335	13.9	19
158	Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	3
157	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016 , 134, 281-294	7.9	28

156	Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. <i>Current Opinion in Neurology</i> , 2016 , 29, 254-62	7.1	37
155	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. <i>Human Molecular Genetics</i> , 2016 , 25, 308-16	5.6	23
154	Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled--MS arising during Tocilizumab therapy for rheumatoid arthritis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 257-8	5	4
153	Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. <i>CNS Drugs</i> , 2016 , 30, 41-51	6.7	19
152	Cytokine profiles show heterogeneity of interferon- γ response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e202	9.1	26
151	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. <i>Molecular and Cellular Proteomics</i> , 2016 , 15, 318-28	7.6	21
150	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1048-60	5	57
149	DNA Vaccination Techniques. <i>Methods in Molecular Biology</i> , 2016 , 1304, 39-50	1.4	1
148	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1005-15	5.5	157
147	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016 , 6, 2073-9	3.2	8
146	Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. <i>Journal of Immunology</i> , 2016 , 196, 4553-65	5.3	12
145	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016 , 87, 1076-84	6.5	61
144	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 18-33	5	16
143	Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. <i>Stem Cells Translational Medicine</i> , 2015 , 4, 252-60	6.9	17
142	Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. <i>Clinical Immunology</i> , 2015 , 160, 133-41	9	3
141	A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis. <i>Human Molecular Genetics</i> , 2015 , 24, 5619-27	5.6	28
140	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015 , 138, 918-31	11.2	103
139	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. <i>Journal of Neuroimmunology</i> , 2015 , 278, 277-9	3.5	13

138	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015 , 138, 1863-74	11.2	302
137	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015 , 12, 48	10.1	22
136	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015 , 52, 848-55	5.8	27
135	Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation. <i>Journal of Neuroimmunology</i> , 2015 , 289, 12-20	3.5	7
134	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. <i>Journal of Neuroimmunology</i> , 2015 , 288, 98-101	3.5	5
133	Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1262-70	5	7
132	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 780-5	5	37
131	Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN- β . <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015 , 2, e154	9.1	15
130	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0134414	3.7	4
129	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1802-10	5	2
128	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24	5	181
127	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015 , 138, 632-43	11.2	42
126	Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1498-512	5	8
125	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015 , 77, 447-57	9.4	43
124	NLRP3 inflammasome is associated with the response to IFN- β in patients with multiple sclerosis. <i>Brain</i> , 2015 , 138, 644-52	11.2	75
123	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014 , 20, 272-82	50.5	103
122	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014 , 272, 51-5	3.5	8
121	Body fluid biomarkers in multiple sclerosis. <i>Lancet Neurology</i> , 2014 , 13, 113-26	24.1	157

120	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon- β therapy in multiple sclerosis. <i>Journal of Medical Genetics</i> , 2014 , 51, 395-400	5.8	17
119	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. <i>Autoimmunity</i> , 2014 , 47, 127-33	3	14
118	Nerve conduction velocity is regulated by the inositol polyphosphate-4-phosphatase II gene. <i>American Journal of Pathology</i> , 2014 , 184, 2420-9	5.8	5
117	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , 2014 , 83, 1210-6	6.5	26
116	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 271, 49-52	3.5	1
115	Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2014 , 76, 231-40	9.4	42
114	Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. <i>Biomarkers in Medicine</i> , 2014 , 8, 653-61	2.3	59
113	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 577-87	5	35
112	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2014 , 1, e47	9.1	8
111	Ancient and recent selective pressures shaped genetic diversity at AIM2-like nucleic acid sensors. <i>Genome Biology and Evolution</i> , 2014 , 6, 830-45	3.9	22
110	N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 2338-43	5.5	42
109	Validation of semaphorin 7A and ala-His-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014 , 11, 181	10.1	22
108	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1602-8	5	33
107	A case of neuromyelitis optica harboring both anti-aquaporin-4 antibodies and a pathogenic mitochondrial DNA mutation for Leber's hereditary optic neuropathy: clinical commentary. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 261	5	2
106	Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 271, 56-9	3.5	6
105	TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. <i>Neurology</i> , 2013 , 80, 2010-6	6.5	19
104	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. <i>Brain</i> , 2013 , 136, 1778-82	11.2	47
103	Treatment with interferon- β does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013 , 255, 102-4	3.5	1

102	Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013 , 263, 152-4	3.5	11
101	SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 524-31	5	14
100	Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon- β treatment. <i>European Journal of Neurology</i> , 2013 , 20, 1390-7	6	24
99	TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013 , 261, 146-8	3.5	5
98	Cellular immune responses in multiple sclerosis patients treated with interferon-beta. <i>Clinical and Experimental Immunology</i> , 2013 , 171, 243-6	6.2	4
97	Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. <i>American Journal of Human Genetics</i> , 2013 , 92, 854-65	11	132
96	Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. <i>Journal of Medical Genetics</i> , 2013 , 50, 25-33	5.8	45
95	Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. <i>Journal of Medical Genetics</i> , 2013 , 50, 140-3	5.8	29
94	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1802-9	5	99
93	Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. <i>PLoS ONE</i> , 2013 , 8, e60994	3.7	23
92	Risk acceptance in multiple sclerosis patients on natalizumab treatment. <i>PLoS ONE</i> , 2013 , 8, e82796	3.7	21
91	Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012 , 245, 98-101	3.5	9
90	Transcriptomics: mRNA and alternative splicing. <i>Journal of Neuroimmunology</i> , 2012 , 248, 23-31	3.5	45
89	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. <i>European Journal of Neurology</i> , 2012 , 19, 899-904	6	42
88	Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 983-90	5	41
87	Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2012 , 9, 139	10.1	31
86	ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. <i>Genes and Immunity</i> , 2012 , 13, 253-7	4.4	37
85	A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. <i>Genes and Immunity</i> , 2012 , 13, 21-8	4.4	49

84	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1193-6	5	19
83	DNA-based vaccines for multiple sclerosis: current status and future directions. <i>Clinical Immunology</i> , 2012 , 142, 76-83	9	29
82	Immunopathogenesis of multiple sclerosis. <i>Clinical Immunology</i> , 2012 , 142, 2-8	9	93
81	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 959-65	5	24
80	Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , 2012 , 78, 1608-11	6.5	15
79	EBV-specific immune responses in patients with multiple sclerosis responding to IFN β therapy. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 605-9	5	15
78	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , 2011 , 2011, 246412	1.1	40
77	Multiple sclerosis: current treatment algorithms. <i>Current Opinion in Neurology</i> , 2011 , 24, 230-7	7.1	47
76	Role of tumour necrosis factor (TNF)- β and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2011 , 166, 338-45	6.2	23
75	Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. <i>Genes and Immunity</i> , 2011 , 12, 110-5	4.4	31
74	Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferon β therapy in multiple sclerosis. <i>Genes and Immunity</i> , 2011 , 12, 466-72	4.4	30
73	Tumor necrosis factor alpha (TNF- α) anti-TNF- β and demyelination revisited: an ongoing story. <i>Journal of Neuroimmunology</i> , 2011 , 234, 1-6	3.5	94
72	IL28B polymorphisms are not associated with the response to interferon- β in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011 , 239, 101-4	3.5	16
71	Risk of multiple sclerosis in children with acute demyelination. <i>Lancet Neurology</i> , 2011 , 10, 399-400	24.1	
70	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. <i>Clinical Immunology</i> , 2011 , 141, 348-56	9	43
69	Pharmacogenomics and multiple sclerosis: moving toward individualized medicine. <i>Current Neurology and Neuroscience Reports</i> , 2011 , 11, 484-91	6.6	35
68	Pharmacogenomics in neurology: current state and future steps. <i>Annals of Neurology</i> , 2011 , 70, 684-97	9.4	23
67	Implication of the Toll-like receptor 4 pathway in the response to interferon- β in multiple sclerosis. <i>Annals of Neurology</i> , 2011 , 70, 634-45	9.4	33

66	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
65	Decision tree based fuzzy classifier of magnetic resonance spectra from cerebrospinal fluid samples. <i>Fuzzy Sets and Systems</i> , 2011 , 170, 43-63	3.7	3
64	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011 , 134, 693-703	11.2	76
63	Interferon β for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. <i>Archives of Neurology</i> , 2011 , 68, 1421-7		34
62	Search for specific biomarkers of IFN β bioactivity in patients with multiple sclerosis. <i>PLoS ONE</i> , 2011 , 6, e23634	3.7	40
61	An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. <i>Revista De Neurologia</i> , 2011 , 52, 321-30	24	6
60	The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. <i>Genes and Immunity</i> , 2010 , 11, 439-45	4.4	71
59	Short commentary on a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 129-32	5	5
58	Brainstem lesions in clinically isolated syndromes. <i>Neurology</i> , 2010 , 75, 1933-8	6.5	136
57	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010 , 34, 1-12		
56	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 55-61	5	45
55	Targeting dendritic cells to treat multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010 , 6, 499-507	15	48
54	Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010 , 30, 727-32	3.5	12
53	IFN-beta pharmacogenomics in multiple sclerosis. <i>Pharmacogenomics</i> , 2010 , 11, 1137-48	2.6	16
52	Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. <i>Journal of Immunology</i> , 2010 , 185, 5392-404	5.3	23
51	Antiviral immune response in patients with multiple sclerosis and healthy siblings. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 355-8	5	15
50	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. <i>Brain</i> , 2010 , 133, 1082-93	11.2	197
49	Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 67, 159-69	9.4	145

48	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. <i>Journal of Neurology</i> , 2010 , 257, 742-6	5.5	18
47	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010 , 352, 23-31	2.5	69
46	Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010 , 222, 70-5	3.5	10
45	B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS. <i>Journal of Neuroimmunology</i> , 2010 , 223, 135-7	3.5	5
44	Orchestrating innate immune responses in multiple sclerosis: molecular players. <i>Journal of Neuroimmunology</i> , 2010 , 225, 5-12	3.5	19
43	Measures in the first year of therapy predict the response to interferon beta in MS. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 848-53	5	182
42	Predicting responders to therapies for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2009 , 5, 553-60	15	101
41	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , 2009 , 73, 1914-22	6.5	470
40	A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. <i>Brain</i> , 2009 , 132, 3353-65	11.2	168
39	Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 972-8		94
38	United Europeans for development of pharmacogenomics in multiple sclerosis network. <i>Pharmacogenomics</i> , 2009 , 10, 885-94	2.6	9
37	HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009 , 210, 116-9	3.5	28
36	Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009 , 213, 142-7	3.5	6
35	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. <i>Clinical Immunology</i> , 2009 , 130, 145-50	9	36
34	Plasma chitotriosidase activity in multiple sclerosis. <i>Clinical Immunology</i> , 2009 , 131, 216-22	9	27
33	Reply: Plasma chitotriosidase activity in multiple sclerosis. <i>Clinical Immunology</i> , 2009 , 133, 284	9	
32	Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. <i>Clinical Immunology</i> , 2009 , 133, 364-74	9	14
31	Plasma levels of 15d-PGJ are not altered in multiple sclerosis. <i>European Journal of Neurology</i> , 2009 , 16, 1197-201	6	5

30	Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. <i>Archives of Neurology</i> , 2008 , 65, 337-44		135
29	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. <i>Neurology</i> , 2008 , 70, 1079-83	6.5	265
28	Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 412-4	5	5
27	Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 479-84	5	97
26	Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 623-629		1
25	Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. <i>Journal of Neurology</i> , 2008 , 255, 1136-41	5.5	20
24	Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. <i>PLoS ONE</i> , 2008 , 3, e3490	3.7	83
23	Genomics in multiple sclerosis--current state and future directions. <i>Journal of Neuroimmunology</i> , 2007 , 187, 1-8	3.5	58
22	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37	5.5	45
21	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 731-6	5	4
20	Altered maturation of circulating dendritic cells in primary progressive MS patients. <i>Journal of Neuroimmunology</i> , 2006 , 175, 183-91	3.5	32
19	Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006 , 180, 147-58	3.5	14
18	Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. <i>Annals of Neurology</i> , 2006 , 59, 344-52	9.4	260
17	Baseline MRI predicts future attacks and disability in clinically isolated syndromes. <i>Neurology</i> , 2006 , 67, 968-72	6.5	209
16	TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. <i>Journal of Neurology</i> , 2006 , 253, 701-6	5.5	14
15	Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans. <i>Bioinformatics</i> , 2005 , 21 Suppl 2, ii180-1	7.2	3
14	Transcription-based prediction of response to IFNbeta using supervised computational methods. <i>PLoS Biology</i> , 2005 , 3, e2	9.7	122
13	Plasma osteopontin levels in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005 , 158, 231-9	3.5	143

12	Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005 , 164, 140-7	3.5	21
11	Is optic neuritis more benign than other first attacks in multiple sclerosis?. <i>Annals of Neurology</i> , 2005 , 57, 210-5	9.4	93
10	Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 618-20	5	7
9	Decreased MMP-9 production in primary progressive multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 376-80	5	19
8	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. <i>Journal of Neuroimmunology</i> , 2003 , 143, 124-8	3.5	33
7	Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 39-43	5	42
6	Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. <i>Journal of Neuroimmunology</i> , 2002 , 126, 205-12	3.5	43
5	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. <i>Annals of Neurology</i> , 2002 , 52, 400-6	9.4	89
4	Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: compound heterozygosity for the IVS2+1G-->A mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family. <i>Annals of Neurology</i> , 2001 , 50, 108-12	9.4	5
3	Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. <i>Journal of Clinical Investigation</i> , 1998 , 102, 671-8	15.9	169
2	The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility		31
1	Biomarkers26-55		